𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A demonstration of androgen and estrogen receptors in a human breast cancer using a new protamine sulfate assay

✍ Scribed by Marc Lippman; Karen Huff


Publisher
John Wiley and Sons
Year
1976
Tongue
English
Weight
514 KB
Volume
38
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Separate receptors for estrogen and androgen are demonstrated in cells from metastic human breast cancer. By criteria of binding affinity, number of binding sites, and specificity of the receptor for different steroids, the receptors are shown to be distinguishable. The protamine sulfate receptor assay technique employed allows both kinds of receptor to be quantified conveniently and reproducibly without interference by plasma steroid-binding components.


πŸ“œ SIMILAR VOLUMES


Reporter gene assay demonstrates functio
✍ Anjana Singh; Simak Ali; Manish S. Kothari; Manuela Tamburo De Bella; Clive Smit πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 160 KB

## Abstract Tamoxifen has contributed to a dramatic reduction in breast cancer mortality and recent results indicate that aromatase inhibitors may further improve survival in some patients. Nevertheless, a substantial proportion of patients become resistant to treatment. To date, with the exception

Histopathologic characterization of huma
✍ Angelika Reiner; Georg Reiner; JΓΌrgen Spona; Michael Schemper; Johann H. Holzner πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 609 KB

A detailed histopathologic analysis of 399 primary breast carcinomas was performed, and several morphologic features were correlated with the estrogen receptor (ER) status. In all cases ER status was determined immunocytochemically by estrogen receptor immunocytochemical assay (ER-ICA). In 359 carci

Evaluation of a displacement assay with
✍ Emanuel Levin; Andrea M. Actis; Silvana Caruso; Hugo Gass; Raquel Romero; NicolΓ‘ πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 95 KB πŸ‘ 2 views

A displacement assay with tamoxifen, based on the relative binding affinity of tamoxifen and estradiol for the estrogen receptor (ER), was proposed in 1990 as prognostic indicator for breast-cancer patients. Validation of its predictive results in relation to the outcome of 73 patients with ER Ψ‰ tum